Literature DB >> 35197605

A bacterial three-hybrid assay for forward and reverse genetic analysis of RNA-protein interactions.

Oliver M Stockert1,2, Chandra M Gravel1,3, Katherine E Berry4,5.   

Abstract

This protocol describes a bacterial three-hybrid (B3H) assay, an in vivo system that reports on RNA-protein interactions and can be implemented in both forward and reverse genetic experiments. The B3H assay connects the strength of an RNA-protein interaction inside of living Escherichia coli cells to the transcription of a reporter gene (here, lacZ). We present protocols to (1) insert RNA and protein sequences into appropriate vectors for B3H experiments, (2) detect putative RNA-protein interactions with both qualitative and quantitative readouts and (3) carry out forward genetic mutagenesis screens. The B3H assay builds on a well-established bacterial two-hybrid system for genetic analyses. As a result, protein-protein interactions can be assessed in tandem with RNA interactions with a bacterial two-hybrid assay to ensure that protein variants maintain their functionality. The B3H system is a powerful complement to traditional biochemical methods for dissecting RNA-protein interaction mechanisms: RNAs and proteins of interest do not need to be purified, and their interactions can be assessed under native conditions inside of a living bacterial cell. Once cloning has been completed, an assay can be completed in under a week and a screen in 1-2 weeks.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35197605     DOI: 10.1038/s41596-021-00657-4

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   17.021


  1 in total

1.  Determinants of RNA recognition by the FinO domain of the Escherichia coli ProQ protein.

Authors:  Ewa M Stein; Joanna Kwiatkowska; Maciej M Basczok; Chandra M Gravel; Katherine E Berry; Mikołaj Olejniczak
Journal:  Nucleic Acids Res       Date:  2020-07-27       Impact factor: 16.971

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.